About Cypre

Cypre partners with pharma and biotech to advance oncology programs from target discovery through IND-enabling studies. Our tumor microenvironment organoids generate MOA and biomarker data across 5+ solid tumor indications.

Who We Are

Cypre is a biotechnology company advancing drug discovery with 3D tumor models that replicate the complexity of the human tumor microenvironment. Founded by scientists and bioengineers and built for translational impact, we specialize in engineering assays that integrate tumor, stromal, and immune components for clinically relevant insights.

Headquartered in San Francisco and built by a specialist team spanning biology, operations, engineering, and data, our platform has been validated in MOA and biomarker studies across six cancer types. We partner with top pharmaceutical companies, biotechs, and academic institutions to generate high-quality efficacy and MOA data—accelerating development timelines and reducing reliance on animal models.

2013

Founded

$

20

m

Product Sales

100

+

Tumor Models

50

+

Clients

FDA-Aligned Organoid Platform Technology

Our Guiding Vision for the Future

Founded by Kolin C. Hribar, PhD, Cypre is driven by a mission to transform oncology through human-relevant tumor models that more accurately predict clinical outcomes. Today, that vision is evolving in groundbreaking ways:

Advancing Animal Tumoroid Research: Pioneering the integration of patient-derived xenografts and animal tumoroids to unlock deeper translational insights and reduce reliance on traditional animal models.
Shaping the Next Generation of Immunotherapy: Building complex, immune-competent tumor microenvironments to better evaluate T cell engagers, checkpoint inhibitors, and novel immunomodulators.
Predicting Treatment Outcomes Before the Clinic: Harnessing multi-modal analytics—spanning cytokines, immune infiltration, and RNA-seq—to forecast therapeutic response and guide early decision-making.
Streamlining IND-Ready Programs: Delivering standardized, high-resolution datasets that meet regulatory expectations and accelerate timelines to first-in-human studies.
Fueling Global Collaborations: Partnering with leading pharmaceutical companies and CROs to drive faster, smarter drug development pipelines worldwide.

Meet the Team

Driven by Science. Grounded in Shared Values.

Collaboration That Elevates

We’re a team-first organization where cross-disciplinary collaboration is core to how we operate. Whether in the lab or in strategy sessions, we bring diverse perspectives together to solve complex challenges and accelerate therapeutic progress.

Innovation With Purpose

From experimental design to product development, we’re driven by scientific curiosity and a commitment to doing things differently. We don’t just follow standards—we redefine them in the pursuit of better cancer therapies.

A Shared Commitment to Patients

Everything we do is rooted in a unified goal: to improve outcomes for people living with cancer. Our shared purpose inspires us to build tools that make drug development smarter, faster, and more human-relevant.

Our team

Kolin C. Hribar, PhD

CEO & Founder

Kolin is the Founder and CEO of Cypre, where he leads the business and scientific development of advanced 3D tumor microenvironment models to accelerate oncology drug discovery. With a background in bioengineering and translational research, Kolin is passionate about building platforms that bridge innovative science with real-world clinical impact.

Ellen Chang

Board Member

Ellen is a board member at Cypre and a strategic force in deep tech investment and national security innovation. As Founding Partner of Syndicate 708 and a senior advisor at BMNT, she brings decades of experience mobilizing capital and leading growth strategies across aerospace, defense, and advanced manufacturing.

Kyle Derham

Board Member

Kyle Derham is a seasoned investor and strategic operator with deep expertise in scaling companies at the intersection of energy, infrastructure, and innovation. As a Partner at Rice Investment Group and board member of multiple public and private ventures, he brings a track record of high-impact capital deployment and company-building across transformative sectors.

Bin Xue, PhD

Director of Research

Bin is the Director of Research at Cypre, where she leads the scientific strategy behind Cypre’s cutting-edge 3D tumor microenvironment models. With a PhD in Cancer Biology and postdoctoral research experience at UC Berkeley, Bin brings deep expertise in oncology, immunology, and high-content analytics to advance preclinical drug discovery.

Prachi Bagadia

Senior Scientist

Prachi Bagadia is a translational immunologist focused on advancing human-relevant tumor models at Cypre. She brings deep expertise from her work in drug discovery at Fibrogen and Amgen, where she contributed to immuno-oncology and inflammation programs. Prachi earned her PhD in Immunology from Washington University in St. Louis.

Mary Janatpour, PhD

Scientific Advisor

Dr. Mary Janatpour is a seasoned oncology-focused scientific leader and CSO with over 25 years of experience in the biotech and pharmaceutical industries. With a PhD in Biomedical Sciences and postdoctoral training in immunology, she brings deep expertise in building biologics pipelines and guiding oncology innovation, serving as a trusted advisor to Cypre in strategic research development and translational application of complex tumor models.

James Trager, PhD

Scientific Advisor

Dr. James Trager is a pioneering scientist and advisor with over 30 years of experience advancing immune and cell therapies for cancer and autoimmune diseases. As the former Chief Scientific Officer at Nkarta and a longtime leader at Dendreon, he brings unparalleled strategic insight into translating innovative science into clinical success.

Linda Masat, PhD

Scientific Advisor

Dr. Linda Masat is a seasoned biopharmaceutical executive with over 18 years of experience leading biologics discovery and preclinical development at companies including Takeda, XOMA, and Abgenix. With a track record that includes advancing over 60 biologic programs and inventing the IL-1β antibody Gevokizumab, she now advises companies on translational strategy, target validation, and preclinical innovation in oncology and immunology.

Bryan Downie, PhD

AI + Data Advisor

Bryan Downie is a scientific advisor to Cypre, bringing deep experience at the intersection of biomarkers, AI, and multi-omics. He is the founder of a stealth-stage company building data-driven tools for translational research and formerly served as Director of Clinical Biomarkers at Gilead. Bryan earned his PhD from the University of Göttingen.